Sugi Predict

Sugi Predict / Compounds / SCHEMBL29469161

SCHEMBL29469161

SCHEMBL29469161

CC1(C)OB(c2cccc3cc[nH]c23)OC1(C)C

nearest known ligand 0.42

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ AHR P35869 1/20 0.42
▸ LPL P06858 3/20 0.39
▸ LIPG Q9Y5X9 3/20 0.39
▸ KEAP1 Q14145 1/20 0.38
▸ NR3C1 P04150 6/20 0.37
▸ PGR P06401 3/20 0.37
▸ NR3C2 P08235 2/20 0.37
▸ AR P10275 2/20 0.37
▸ PDPK1 O15530 1/20 0.37
▸ BCHE P06276 3/20 0.35
▸ JAK2 O60674 3/20 0.33
▸ BTK Q06187 3/20 0.33
▸ BACE1 P56817 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2028185 1.00 AHR (0.42) AHRLPLLIPGKEAP1NR3C1
SCHEMBL15796865 0.83 LPL (0.35) AHRLPLLIPGKEAP1NR3C1
SCHEMBL16048357 0.78 TNF (0.38) LPLLIPGNR3C1
SCHEMBL21624119 0.78 LPL (0.39) AHRLPLLIPGNR3C1PGR
SCHEMBL21624076 0.78 LPL (0.33) LPLLIPG
SCHEMBL15563246 0.78 LPL (0.33) LPLLIPG
SCHEMBL2171238 0.76 CA12 (0.46) LPLLIPGJAK2BTK
SCHEMBL16972292 0.76 NR3C1 (0.36) AHRLPLLIPGNR3C1PGR
SCHEMBL24595249 0.76 LPL (0.33) LPLLIPG
SCHEMBL30484203 0.76 LPL (0.33) LPLLIPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078124-A1 METHODS OF PREPARING ERGOLINE ANALOGS UNIV CALIFORNIA (US) 2026-03-19 — — US claimed
WO-2024059495-A1 METHODS OF PREPARING ERGOLINE ANALOGS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-03-21 — — WO claimed
US-12637464-B2 Tetracyclic compounds for treating brain disorders THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2026-05-26 — — US disclosed
US-20260078124-A1 METHODS OF PREPARING ERGOLINE ANALOGS UNIV CALIFORNIA (US) 2026-03-19 — — US disclosed
US-20250388560-A1 AROMATIC COMPOUND AND USE THEREOF HITGEN INC (CN) 2025-12-25 — — US disclosed
EP-4653421-A1 AROMATIC-RING COMPOUND AND USE THEREOF Hitgen Inc. (CN) 2025-11-26 — — EP disclosed
WO-2025080608-A1 DESAMIDE ISOTRYPTAMINE TETRACYCLES FOR TREATING BRAIN DISORDERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-04-17 — — WO disclosed
WO-2025080609-A1 ISOTRYPTAMINE TETRACYCLES FOR TREATING BRAIN DISORDERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-04-17 — — WO disclosed
US-20250057822-A1 PSYCHOPLASTOGENS FOR TREATING HEARING-RELATED DISORDERS UNIV CALIFORNIA (US) 2025-02-20 — — US disclosed
US-12083121-B2 Substituted piperazines as KRAS G12C inhibitors AMGEN INC. (US) 2024-09-10 — — US disclosed
WO-2024179572-A1 AROMATIC-RING COMPOUND AND USE THEREOF 成都先导药物开发股份有限公司 2024-09-06 — — WO disclosed
US-20230159536-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-05-25 — — US disclosed
EP-4125914-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2023-02-08 — — EP disclosed
CN-115427044-A Pyrrolopyrimidines as complement inhibitors 拜奥克里斯特制药公司 2022-12-02 — — CN disclosed
WO-2022221415-A2 TETRACYCLIC COMPOUNDS FOR TREATING BRAIN DISORDERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-10-20 — — WO disclosed
US-20220298135-A1 5-HETEROARYL-PYRIDIN-2-AMINE COMPOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS DOMAIN THERAPEUTICS (FR) 2022-09-22 — — US disclosed
EP-4010328-A1 5-HETEROARYL-PYRIDIN-2-AMINE CONFOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS Domain Therapeutics (FR) 2022-06-15 — — EP disclosed
US-20220175782-A1 KRAS G12C INHIBITORS AND METHODS OF USING THE SAME AMGEN INC. 2022-06-09 — — US disclosed
CN-114269730-A 5-heteroaryl-pyridin-2-amine compounds as neuropeptide FF receptor antagonists 多曼治疗学公司 2022-04-01 — — CN disclosed
US-11285156-B2 Substituted piperazines as KRAS G12C inhibitors AMGEN INC. (US) 2022-03-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11285156-B2 Substituted piperazines as KRAS G12C inhibitors KRAS, NRAS, HRAS AHR 627/4885LPL 4301/4885LIPG 3180/4885
US-20250057822-A1 PSYCHOPLASTOGENS FOR TREATING HEARING-RELATED DISORDERS PSAP, CYP27A1, PSAT1 AHR 1466/4885LPL 3189/4885LIPG 4404/4885
US-20230159536-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS C5, C9, C1QBP AHR 1296/4885LPL 1773/4885LIPG 984/4885
US-12083121-B2 Substituted piperazines as KRAS G12C inhibitors KRAS, NRAS, HRAS AHR 627/4885LPL 4301/4885LIPG 3180/4885
US-20250388560-A1 AROMATIC COMPOUND AND USE THEREOF RNF213, RNF10, TRIM4 AHR 886/4885LPL 4330/4885LIPG 4351/4885
US-12637464-B2 Tetracyclic compounds for treating brain disorders GRIN2C, GRIN2D, GRIN1 AHR 3466/4885LPL 3267/4885LIPG 3937/4885
US-20260078124-A1 METHODS OF PREPARING ERGOLINE ANALOGS HTR1A, HTR2A, HTR7 AHR 1232/4885LPL 581/4885LIPG 653/4885
US-20220175782-A1 KRAS G12C INHIBITORS AND METHODS OF USING THE SAME KRAS, NRAS, HRAS AHR 3194/4885LPL 3608/4885LIPG 1590/4885
US-20220298135-A1 5-HETEROARYL-PYRIDIN-2-AMINE COMPOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS NPFFR2, NPFFR1, OPRL1 AHR 713/4885LPL 2517/4885LIPG 3970/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.